Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

10.020
-0.230-2.24%
Volume:1.78M
Turnover:18.09M
Market Cap:10.54B
PE:-27.07
High:10.320
Open:10.150
Low:9.945
Close:10.250
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:1.18
T/O Rate:0.17%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-18.45%
ROA:-14.45%
PB:4.67
PE(LYR):-27.07
PS:4454.37

Loading ...

Ascletis Pharma - to Use up to Hk$300 Mln for Share Repurchase

THOMSON REUTERS
·
Jun 30

Ascletis Pharma Plans up to Hk$300 Million Share Buyback Under Mandate

Reuters
·
Jun 30

Ascletis Revises Articles: Sets US$700,000 Authorised Capital, Enables Virtual Meetings and Three-Year Director Rotation

Bulletin Express
·
Jun 29

Ascletis Pharma Holds Annual Shareholder Meeting

Reuters
·
Jun 29

Ascletis Pharma Shareholders Approve Amended and Restated Bylaws

Reuters
·
Jun 29

ASCLETIS-B Shares Surge Over 7% on FDA IND Approval for ASC35 Phase I Study and GIC's Consistent Share Purchases

Stock News
·
Jun 29

Ascletis executes HKD 1.93 million on-market share buyback; outstanding share count steady at 1.07 billion

Bulletin Express
·
Jun 26

Ascletis Pharma Files HKEX Next-day Disclosure Return on Share Repurchase for Cancellation

Reuters
·
Jun 26

Is Ascletis Pharma (SEHK:1672) Undervalued On FDA Clearance For ASC35?

Simply Wall St.
·
Jun 24

ASCLETIS PHARMA CONDUCTS HK$2.02 MILLION SHARE BUYBACK

Stock News
·
Jun 24

Ascletis Pharma Gets US FDA Nod for Obesity Drug Trial

MT Newswires Live
·
Jun 23

ASCLETIS-B Receives FDA Clearance for Phase I Study of Its Monthly Subcutaneous GLP-1R/GIPR Dual Agonist Peptide ASC35 in Obesity

Stock News
·
Jun 23

Ascletis Announces U.S. FDA Ind Clearance for Phase I Study of Once-Monthly Subcutaneously Administered Glp-1R/Gipr Dual Peptide Agonist, Asc35, for the Treatment of Obesity

THOMSON REUTERS
·
Jun 23

Ascletis wins US FDA IND clearance for Phase I study of monthly obesity drug ASC35

Reuters
·
Jun 23

Ascletis Pharma - Receives U.S. FDA Ind Clearance for Phase I Study of Asc35 for Obesity

THOMSON REUTERS
·
Jun 23

HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%

Tiger Newspress
·
Jun 23

ASCLETIS-B Executes Share Buyback on June 22, Spending HK$1.901 Million

Stock News
·
Jun 22

Ascletis Pharma files HKEX next-day return disclosing share repurchase for cancellation

Reuters
·
Jun 22

ASCLETIS-B Executes Share Buyback Totaling HK$1.97 Million

Stock News
·
Jun 17

Ascletis Pharma files HKEX next-day disclosure return on share repurchase for cancellation

Reuters
·
Jun 17